Robert Alan Star

US Patent:

6852842, Feb 8, 2005

Filed:

Aug 26, 2002

Appl. No.:

10/229316

Inventors:

Martin W. Brechbiel - Annandale VA, US
Robert A. Star - Bethesda MD, US
Hisataka Kobayashi - Nishinomiya, JP

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

C07F005/00

US Classification:

534 15, 424 111, 424 91, 424 936

Abstract:

Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.

US Patent:

6951761, Oct 4, 2005

Filed:

Aug 30, 2002

Appl. No.:

10/233193

Inventors:

Robert A. Star - Bethesda MD, US
Takehiko Miyaji - Rockville MD, US
Stephen M. Hewitt - Potomac MD, US
Lance A. Liotta - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G01N001/36
G01N001/00
G01N001/30
A01N001/02
C12Q001/00

US Classification:

436174, 436 8, 436 63, 435 11, 435 4, 435 5, 435 6, 435 71, 435 405, 435 911, 4353071, 435810

Abstract:

This disclosure relates to CryoArrays, which permit the analysis of samples (such as protein, nucleic acid, virus, or cell samples) in arrays that are prepared at low temperatures. Because CryoArrays are constructed as a block of substantially columnar samples, the block can be sliced to provide a plurality of identical or substantially identical individual arrays. The individual arrays can be used for parallel analysis of the same array feature set, for instance with different probes or under different conditions. Also provided are methods of making CryoArrays, devices for making CryoArrays, and kits.

US Patent:

20050042692, Feb 24, 2005

Filed:

Jul 30, 2004

Appl. No.:

10/903324

Inventors:

Robert Star - Bethesda MD, US
Hiroshi Murakami - Miyagi, JP
Lance Liotta - Bethesda MD, US
Kenneth Spring - Rockville MD, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567

US Classification:

435007200, 435006000

Abstract:

Methods are disclosed for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents are also included. A laser capture microdissection apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed.

US Patent:

20060100743, May 11, 2006

Filed:

Apr 22, 2005

Appl. No.:

11/113212

Inventors:

Seth Townsend - Skaneateles NY, US
Christopher Komanski - Orlando FL, US
Richard Boyer - Cooper City FL, US
Nathan Tedford - Somerville MA, US
Derek Fine - Baltimore MD, US
Robert Star - Bethesda MD, US

Assignee:

Renal Diagnostic Inc. - Cambridge MA

International Classification:

G05D 21/00

US Classification:

700266000

Abstract:

A real-time, non-invasive system and method for determining the level of an analyte of interest in the urine of a patient is disclosed. The system and method uses the measured level of an analyte of interest to detect the onset of acute renal failure (ARF) as early as possible to prevent that patient from developing the disease or mitigating the effects of the disease. The system and method may be used to monitor the recovery of a patient after an ARF diagnosis. Preferably, the analyte of interest is creatinine or urea. The system may be placed in the urine drain line of a patient between a Foley catheter or other urinary drain and a urine collection bag. The system makes substantially continuous measurements of the urine flow rate and the concentration of the analyte of interest to determine the mass excretion rate of the analyte so it may be monitored to detect if the patient experiences a delta change in the mass excretion rate of an analyte that is indicative of the onset of ARF or a change in renal function.

US Patent:

6790636, Sep 14, 2004

Filed:

Jun 13, 2001

Appl. No.:

09/881446

Inventors:

Robert A. Star - Bethesda MD
Hiroshi Murakami - Miyagi, JP
Lance A. Liotta - Bethesda MD
Kenneth R. Spring - Rockville MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G01N 3348

US Classification:

435 405, 435 71, 435 4052, 436164, 436172

Abstract:

Methods are disclosed for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents are also included. A laser capture microdissection apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed.

US Patent:

20220291094, Sep 15, 2022

Filed:

Apr 8, 2022

Appl. No.:

17/716606

Inventors:

- Bethesda MD, US
Joon-Yong Chung - Rockville MD, US
Candice D. Perry - Gaithersburg MD, US
Robert A. Star - Bethesda MD, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

G01N 1/30

Abstract:

Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.

US Patent:

20210094029, Apr 1, 2021

Filed:

Apr 26, 2018

Appl. No.:

16/606555

Inventors:

- Bethesda MD, US
Robert A. Star - Bethesda MD, US
Jeffrey C. Hanson - Bethesda MD, US
Hiroshi Kojima - Bethesda MD, US
Russell Bandle - Bethesda MD, US
Armando Filie - Bethesda MD, US

Assignee:

THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES - Bethesda MD

International Classification:

B01L 3/00
A61B 10/00
A61B 10/02

Abstract:

A container comprising:

US Patent:

20200041389, Feb 6, 2020

Filed:

Nov 11, 2016

Appl. No.:

15/774480

Inventors:

- Bethesda MD, US
Joon-Yong Chung - Rockville MD, US
Candice D. Perry - Gaithersburg MD, US
Robert A. Star - Bethesda MD, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

G01N 1/30

Abstract:

Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.